Table 1.
Baseline characteristics in phase 1
|
18–59 years |
≥60 years |
Total (n=192) | |||||
|---|---|---|---|---|---|---|---|
| 2 μg (n=32) | 4 μg (n=32) | 8 μg (n=32) | 2 μg (n=32) | 4 μg (n=32) | 8 μg (n=32) | ||
| Age, years | |||||||
| 18–29 | 2 (6%) | 10 (31%) | 3 (9%) | NA | NA | NA | 15 (8%) |
| 30–39 | 9 (28%) | 8 (25%) | 12 (38%) | NA | NA | NA | 29 (15%) |
| 40–49 | 15 (47%) | 8 (25%) | 11 (34%) | NA | NA | NA | 34 (18%) |
| 50–59 | 6 (19%) | 6 (19%) | 6 (19%) | NA | NA | NA | 18 (9%) |
| 60–69 | NA | NA | NA | 26 (81%) | 22 (69%) | 28 (88%) | 76 (40%) |
| 70–79 | NA | NA | NA | 6 (19%) | 10 (31%) | 3 (9%) | 19 (10%) |
| ≥80 | NA | NA | NA | 0 | 0 | 1 (3%) | 1 (1%) |
| Mean | 42·7 (8·1) | 37·7 (12·2) | 40·1 (8·6) | 65·90 (4·1) | 67·5 (4·1) | 67·5 (4·0) | 53·7 (15·6) |
| Sex | |||||||
| Male | 11 (34%) | 16 (50%) | 17 (53%) | 20 (62%) | 17 (53%) | 9 (28%) | 90 (47%) |
| Female | 21 (66%) | 16 (50%) | 15 (47%) | 12 (38%) | 15 (47%) | 23 (72%) | 102 (53%) |
Data are n (%) or mean (SD). NA=not applicable.